Last updated: February 13, 2026
Overview
NDC 64380-0760 is marketed as Dexpramipexole, an investigational drug designed for neurological conditions, notably Amyotrophic Lateral Sclerosis (ALS). Its commercial status remains unconfirmed, as regulatory and patent data suggest it is still in clinical trial phases or pre-market assessment.
Market Landscape
Indication and Market Size
- ALS affects approximately 6,000 new cases annually in the U.S., with a prevalence of about 25,000 patients.
- Current approved treatments, such as riluzole and edaravone, generate combined U.S. sales estimated at $300 million annually (IQVIA, 2022).
- There is unmet demand for effective ALS therapies; potential market penetration depends on trial success, regulatory approval, and competitive landscape.
Competitive Environment
- Existing treatments are limited; riluzole prolongs survival by 3-6 months.
- Edaravone slows functional decline but has limited efficacy.
- No approved disease-modifying agents for ALS; several candidates in development, including BM213, tofersen, and others, with varying trial statuses.
Regulatory and Development Status
- Phase 2 clinical trials show promising safety profiles; efficacy data are preliminary.
- FDA and EMA approval are pending, with no definitive timelines.
- Market entry hinges on positive trial outcomes, regulatory acceptance, and intellectual property rights.
Pricing Projections
Assuming eventual market approval, pricing estimates for Dexpramipexole are based on analogous ALS drugs:
| Parameter |
Details |
| Current ALS drug prices (annual) |
Riluzole: ~$1,200; Edaravone: ~$50,000 |
| Cost drivers |
Dose frequency, manufacturing complexity, value proposition, insurer reimbursement policies |
| Estimated launch price (Year 1) |
$40,000 – $50,000 per year per patient (targeting disease modification) |
| Potential pricing factors |
Market exclusivity, patent protections, competition, payer negotiation strength |
Price decline over time is expected as biosimilars and generics enter the market. A typical 15-25% annual reduction in price is common post-launch, depending on patent status and competitor activity.
Revenue Forecasts
Base scenario:
- Year 1: 1,000 patients treated within 3 years of market launch
- Adoption rate: 25–50% of diagnosed patients
- Annual revenue: $40,000 x 1,000 = $40 million
Long-term:
- With slow adoption and market growth, revenues could reach $100–200 million annually within five years.
Market Risks and Opportunities
- Risks: Failure to demonstrate clear clinical benefit; regulatory delays; competitive dynamics; high development costs.
- Opportunities: First-in-class positioning; companion diagnostics; securing orphan drug designation for market exclusivity; partnerships for manufacturing and distribution.
Key Takeaways
- NDC 64380-0760 has potential in the high-demand ALS market but remains in early clinical stages.
- The market size for ALS drugs suggests peak annual revenues could reach hundreds of millions post-approval.
- Pricing likely to be in the $40,000–$50,000 range annually per patient, with a decline over time.
- Revenue prospects depend heavily on successful trial outcomes and regulatory approval timelines.
- Competition, patent strength, and market access negotiations will influence commercialization success.
Frequently Asked Questions
-
What is the current development status of NDC 64380-0760?
It remains in clinical trial phases with no approved indication. Details on ongoing trials are limited.
-
What are the primary competitors for this drug in the ALS space?
Riluzole and edaravone are the main approved therapies. Other candidates include tofersen and BM213 in development stages.
-
What factors could impact the launch price of Dexpramipexole?
Efficacy data, patent protections, manufacturing costs, and negotiations with payers influence pricing.
-
How does the market size influence revenue potential?
With roughly 6,000 new ALS cases annually in the U.S. and higher prevalence nationally, peak sales could approximate $100–200 million annually if adopted widely.
-
What are the key risks to market entry?
Clinical efficacy doubts, regulatory hurdles, competitive pressures, and reimbursement challenges pose significant risks.
Citations
- IQVIA. (2022). Top Drugs by Sales in ALS.
- FDA. (2022). Regulatory Status of ALS Treatments.
- GlobalData. (2023). ALS Treatment Pipeline and Market Forecasts.
